Commercial Determinants of Health¶

Trace population health and health inequity through the systems, actors, products, practices, and pathways of paid or commercially organized activity pursuing a commercial or revenue-sustaining objective—including profit, growth, cost recovery, market share, or return—and include beneficial as well as harmful effects.

Version: v1 · 2026-08-30 · History
Domain-specific #: 1508
Origin domain: public health
Subdomain: social and structural determinants of health
Aliases: CDoH

Core Idea¶

Commercial Determinants of Health (CDoH) is the public-health causal framework for tracing how commercial actors and the political-economic environment of commerce shape population health and health inequity. The World Health Organization defines the field broadly around private-sector activities that affect health directly or indirectly, positively or negatively, including commercial activity and the environment in which it occurs.^[1] The 2023 Lancet framework condenses the identity as the systems, practices, and pathways through which commercial actors drive health and health inequity.^[2]

The framework moves analysis upstream from an individual's final behavior or diagnosis. A purchase, diet, injury, exposure, or treatment choice is embedded in product portfolios, pricing, marketing, distribution, employment, supply chains, research funding, lobbying, legal strategy, financial practice, and the wider rules that allocate commercial power. Those practices change what is available and affordable, which preferences are cultivated, what evidence becomes salient, how workplaces and environments are organized, which policies pass, and who bears benefit or harm. The result is a causal chain from commercial organization to conditions of exposure and protection to population outcomes.

The influential 2016 formulation emphasized private-sector strategies that promote health-damaging products and choices.^[3] Subsequent work broadened the field from harmful commodities and named corporate tactics to diverse commercial actors, signed health effects, and the political-economic systems that enable or redirect them. The earlier harm-focused route remains central evidence, but it is no longer the whole extension of the concept.

The locked identity is:

paid or commercially organized activity pursuing a commercial or revenue-sustaining objective—including profit, growth, cost recovery, market share, or return—plus actor attributes + one or more product, service, labour, supply-chain, marketing, scientific, political, reputational, legal, or financial practices + a documented pathway that changes exposure, opportunity, information, policy, material conditions, or access + population-health consequence with direction, magnitude, distribution, and uncertainty + feedback through markets, governance, and accumulated power -> a commercial determinant account of health and health inequity.

The framework is signed, not accusatory by definition. Tobacco promotion, unsafe labor, pollution, regulatory interference, or unaffordable access can worsen health; essential medicines, assistive technologies, safer product design, paid leave, living wages, and health-promoting reformulation can improve it. WHO explicitly recognizes both directions, and the actor framework developed by Lacy-Nichols and colleagues warns against collapsing all commercial entities into one undifferentiated harmful class.^[1]^[4] CDoH analysis asks which actor, practice, pathway, population, and outcome under which enabling system? It does not answer “private sector” before evidence is examined.

Structural Signature¶

Sig role-phrases:

the commercial actor — an entity engaged in paid or commercially organized activity pursuing a commercial or revenue-sustaining objective, characterized rather than treated as interchangeable with every business
the actor attributes and portfolio — scale, ownership, resources, products and services, organization, transparency, market position, and dependence on particular revenue streams
the commercial objective — the revenue, growth, cost, market-share, or return imperative that makes a practice intelligible without assuming malicious intent
the commercial practice — product design, production, pricing, marketing, distribution, employment, supply chain, finance, science, lobbying, litigation, political spending, partnership, or reputation management
the enabling commercial system — trade, finance, tax, corporate, media, labor, regulatory, and governance rules and norms that permit, reward, constrain, or redirect the practice
the proximate pathway — the mechanism by which practice changes availability, affordability, preference, information, policy, exposure, working conditions, environmental quality, or access to protective goods
the intermediate determinant — a behavioral, social, environmental, occupational, economic, or health-system condition through which health changes
the population-health outcome — morbidity, mortality, injury, mental health, communicable-disease risk, wellbeing, or protective benefit measured beyond an anecdotal individual case
the equity distribution — how exposure and outcome differ by income, age, race or ethnicity, gender, occupation, geography, disability, country, or political power
the direction and counterfactual — beneficial, harmful, mixed, or uncertain effect compared with a credible alternative commercial or policy arrangement
the power-and-feedback loop — accumulated resources can shape rules, evidence, preferences, and future market position, reinforcing or constraining the original pathway
the intervention surface — product, practice, firm, market, governance, or system level at which public-health action can alter the pathway

Recognition test. A case instantiates Commercial Determinants of Health when it identifies a commercial actor or system, a specific practice or omission connected to commercial objectives, a plausible and evidence-bearing pathway into conditions that affect health, a population-level outcome or risk/protective factor, and the distribution of that effect. A complete account also distinguishes actor attributes from practices, records positive and negative effects where both exist, and names the policy or market context enabling the route. “A company exists near a health problem,” “consumers chose badly,” or “profits are high” does not pass without the causal bridge.

What It Is Not¶

Not a synonym for every social determinant of health. Housing, education, discrimination, and public policy have noncommercial causes as well as commercially mediated ones. CDoH identifies the commercial contribution.
Not a list of unhealthy commodities. Products are one pathway; labor, supply chains, political activity, science, finance, and structural rules can matter even when the focal product is not intrinsically harmful.
Not a claim that all commerce damages health. The sign must be determined. Medicines, safety devices, decent work, and product reformulation can protect health.^[1]
Not limited to transnational corporations. Commercial actors range from microenterprises to multinationals and differ in portfolios, practices, resources, organization, and transparency.^[4]
Not reducible to corporate intent or misconduct. Ordinary pursuit of a legal revenue model can generate harmful or beneficial population effects without a secret plan; the pathway, not inferred motive, carries the causal claim.
Not merely consumer choice. Choice can mediate a pathway, but availability, price, marketing, information, default conditions, and policy are upstream variables rather than background noise.
Not identical to an externality. Some CDoH effects are unpriced third-party spillovers, but others operate through purchased products, employment conditions, political influence, or access to beneficial goods.
Not identical to conflict of interest or regulatory capture. Each is one possible political or institutional pathway; neither covers the product, labor, market, and positive-health routes.
Not a firm-level ESG score. CDoH can inform assessment, but its unit is a causal relationship across actor, practice, system, population, and outcome, not one composite corporate rating.
Not proof from association alone. A market trend and a disease trend can covary because of confounding, reverse causation, or shared drivers. CDoH claims still require causal evidence and calibrated uncertainty.

Scope of Application¶

CDoH analysis applies across tobacco, alcohol, ultra-processed foods, sugar-sweetened beverages, gambling, firearms, automobiles, pharmaceuticals, health care, digital platforms, fossil fuels, mining, agriculture, finance, housing, transport, and many other sectors. It also applies to cross-sector practices: targeted marketing, price discrimination, research sponsorship, lobbying, litigation, tax strategy, labor contracting, procurement, supply-chain control, mergers, and political donations.

The unit of analysis can be one product-practice pathway, one firm or industry, a portfolio, a population, a country, or a global commercial system. Mialon's review organized earlier literature around unhealthy commodities, harmful business/market/political practices, and wider global drivers; the later Lancet framework extends the causal model across actor diversity, systems, practices, pathways, and power.^[5]^[2]

Scope discipline matters. The framework should not assign a population outcome wholly to commerce when public provision, culture, household resources, biology, or other determinants contribute. It should not generalize from one industry to all actors or from one jurisdiction to all governance contexts. Nor should “positive contribution” be credited without a counterfactual: providing a beneficial product may coexist with pricing, access, labor, lobbying, or environmental practices that create offsetting harm. The proper output can be mixed.

Clarity¶

The abstraction separates four commonly conflated layers:

Actor: who is acting, with what portfolio, scale, ownership, resources, and market position?
Practice: what did the actor do or omit—design, price, market, hire, pollute, fund, lobby, litigate, distribute, disclose, or reform?
Pathway: what changed between that practice and health—exposure, access, evidence, preference, policy, work, income, environment, or service conditions?
Outcome and distribution: which health measure moved, for which population, in which direction, compared with what alternative?

This layered account prevents actor labels from substituting for mechanism. It also prevents a product's average effect from hiding distribution. A service can improve overall access while widening geographic or income inequity; a harmful product can be marketed most intensely to groups with the least political power. CDoH therefore treats health equity as an outcome dimension, not an optional ethical afterword.

The framework also clarifies levels of intervention. A warning label acts on product information; an advertising restriction acts on marketing; a conflict-of-interest rule acts on policy influence; antitrust acts on market structure; labor law acts on working conditions; tax and trade reform act on system incentives. Matching the intervention level to the diagnosed pathway avoids treating education as the universal remedy for commercially structured exposure.

No one lever exhausts the framework. Friel and colleagues organize future action across economic models, international rules, public regulation, commercial compliance, alternative business forms, and civil-society mobilization, reflecting the same requirement to match response level to causal level.^[6]

Manages Complexity¶

Population health rarely follows one commercial cause. A firm's products, marketing, supply chain, labor model, financing, and political activity can act jointly, while multiple firms share distributors, trade associations, media channels, and regulatory environments. CDoH manages this complexity with a causal map whose nodes remain separately observable: actor attributes, practices, enabling systems, intermediate determinants, outcomes, and equity strata.

The map supports triangulation. Product-sales and exposure data can test availability; advertising archives can test preference-shaping; lobbying records and policy timelines can test political pathways; funding disclosures and citation patterns can test scientific influence; occupational surveillance can test labor effects; environmental monitoring can test production externalities; and epidemiology can test the exposure-outcome bridge. Evidence can be strong at one link and weak at another without forcing an all-or-nothing conclusion.

It also makes feedback visible. Revenue finances marketing, litigation, research, and political activity; those practices can protect permissive rules or create preferences; permissive rules and preference then expand revenue and actor power. Gilmore and colleagues distinguish structural, instrumental, and discursive forms of commercial power within this wider system.^[2] The framework can therefore explain persistence that a one-time product-risk estimate cannot.

Abstract Reasoning¶

A useful CDoH representation is a signed multilevel causal graph:

\[ A,S \rightarrow P \rightarrow D \rightarrow H,Q, \]

where \(A\) denotes actor attributes, \(S\) the enabling commercial system, \(P\) a practice, \(D\) the intermediate determinant or exposure, \(H\) the population-health outcome, and \(Q\) its equity distribution. Feedback arrows return from revenue, market share, legitimacy, and accumulated power to \(A\), \(S\), and future \(P\). This is not an estimable equation by itself; it is a declaration of what must be measured and where competing explanations enter.

The framework supports decomposition. A harmful total effect can contain a positive product benefit and a larger negative access or pollution effect. A positive average effect can coexist with a negative distributional effect. A political pathway can operate by blocking regulation, delaying it, weakening enforcement, or shifting the evidentiary standard. A counterfactual can be another firm practice, another market arrangement, public provision, or no product at all; choosing it explicitly is part of the claim.

It also supports intervention reasoning. If the product is useful but access is inequitable, redesign pricing or provision rather than ban the product. If a product is inherently hazardous and marketing expands initiation, product and marketing controls are closer to the causal source than individual education alone. If evidence production is distorted, disclosure may be necessary but insufficient when funding concentration controls which questions are studied. The causal graph tells where an intervention enters and which downstream links should respond.

Knowledge Transfer¶

The actor–practice–pathway–outcome structure transfers across public-health topics. A tobacco analyst, an occupational-health researcher, and a digital-platform researcher can use the same questions: what is sold, how revenue is made, which practice changes exposure or governance, who is affected, and how power feeds back. Methods for documenting political activity or scientific influence can likewise transfer across industries while remaining sensitive to sector differences.

Transfer stops where the domain accent begins. “Health” requires epidemiologic outcomes and risk or protective factors; “equity” requires population distributions; “commercial” requires paid or commercially organized activity pursuing a commercial or revenue-sustaining objective—including profit, growth, cost recovery, market share, or return; and causal claims require health-specific evidence. Applying the vocabulary to a noncommercial public agency or to an individual's isolated purchase without a population pathway is not free transfer but a category change.

Examples¶

Canonical¶

Marketing a high-sugar beverage to adolescents. A beverage producer earns revenue from repeated consumption and uses youth-oriented advertising, sponsorship, price promotions, and broad retail placement. These practices increase exposure, availability, desirability, and purchase. Higher habitual intake can contribute to diet-related risk and disease, while marketing intensity and affordable alternatives may vary by neighborhood and income. WHO identifies product design, price-setting, targeted marketing, and unhealthy diets among material CDoH routes.^[1]

Mapped back:

actor and objective: beverage producer seeking sales and market share
practice: product formulation, targeted promotion, sponsorship, price, and distribution
pathway: altered preference, availability, affordability, and consumption
intermediate determinant: dietary exposure
outcome: population risk of obesity, type 2 diabetes, and cardiovascular disease, estimated with epidemiologic evidence rather than assumed from advertising alone
equity: differential youth exposure and access to alternatives
system: advertising rules, school sponsorship policy, retail zoning, tax, and media infrastructure
intervention surface: product reformulation, marketing restriction, pricing policy, procurement, and access to healthier substitutes.

Applied / In Practice¶

A commercially supplied health-protective product. A manufacturer develops and distributes a safe, effective assistive device or essential medicine. Product design and distribution increase functional capacity or reduce disease, while pricing, patent, procurement, and geography determine who can obtain the benefit. WHO includes essential medicines, health technologies, safety devices, better working conditions, and health-promoting reformulation as beneficial commercial pathways.^[1]

Mapped back:

actor and objective: commercial producer earning revenue from a protective good
practice: research, quality-controlled production, pricing, licensing, and distribution
pathway: improved availability and access to effective prevention or treatment
outcome: reduced morbidity or improved functioning
equity question: whether price and distribution widen or narrow access gaps
mixed-effect check: beneficial product effects do not erase labor, environmental, lobbying, or exclusionary-pricing harms if those are present
intervention surface: procurement, quality regulation, tiered pricing, competition, public provision, or access agreements.

Worked intervention — investigating a proposed youth-marketing restriction. Begin with a product-specific causal graph rather than a general statement about “industry.” Identify the firms and trade associations; collect advertising placement and spending, retail availability, prices, and audience exposure by age and neighborhood; test the exposure-to-purchase and purchase-to-health-risk links; document lobbying, litigation, or research sponsorship around the policy; and specify the counterfactual restriction. Pre-register outcome and equity measures. After implementation, compare exposure, sales, substitution, and health intermediates across affected and comparison populations. If firms shift spending to unregulated digital channels or replace the product with an equivalent one, the intervention has changed the route rather than closed it.

Structural Tensions¶

T1: Economic benefit ↔ health harm. Jobs, tax revenue, convenience, and consumer surplus can coexist with morbidity or inequity. Diagnostic: the same actor-practice package has effects of different signs across outcome columns rather than one moral score.

T2: Positive contribution ↔ reputation strategy. A beneficial program can improve health or function mainly as legitimacy for a harmful portfolio. Diagnostic: the program's attributable benefit is small or weakly coupled to the firm's dominant health footprint, while reputational exposure is large.

T3: Individual choice ↔ commercially shaped conditions. People choose, but menus, defaults, price, availability, and promotion shape the choice set. Diagnostic: behavior changes when the commercial environment changes while individual knowledge is held roughly constant.

T4: Actor diversity ↔ analytic tractability. “Private sector” is too coarse, but firm-by-firm detail can obscure shared practices. Diagnostic: conclusions reverse when actors are stratified by portfolio, scale, resources, organization, or transparency.^[4]

T5: Proximate evidence ↔ system causation. Product exposure is easier to estimate than trade, tax, finance, or power effects. Diagnostic: the causal map has precise downstream coefficients but unsupported arrows at the rule-setting level.

T6: Partnership ↔ conflict of interest. Commercial expertise and capacity can improve delivery while revenue dependence can redirect priorities. Diagnostic: the partner controls agenda, evidence, or evaluation in a domain where the proposed policy threatens its business model.

T7: National regulation ↔ transnational mobility. Health authority is jurisdictional while capital, products, platforms, and lobbying strategies cross borders. Diagnostic: exposure or production shifts to a weaker jurisdiction after local control.

T8: Framework reduction ↔ framework autonomy. Externality, Conflict of Interest, Regulatory Capture, and Market Power explain important routes but not the complete actor–practice–system–health–equity map. Diagnostic: removing any one familiar mechanism leaves other verified commercial pathways intact, while removing the causal bridge to population health destroys the CDoH claim.

Structural–Framed Character¶

Commercial Determinants of Health lies decisively on the framed side of the structural–framed spectrum. The causal-chain skeleton is structural, but its identity is constituted by public-health, commercial, political-economic, and equity semantics.

Across the five diagnostics: vocabulary travels poorly—commercial actor, population health, risk factor, health inequity, lobbying, and health policy retain field meanings; evaluative weight is moderate—the framework is sign-neutral in definition but public-health evaluation privileges health and equity; institutional origin is moderate—academic public health and WHO governance stabilize the terminology without alone defining truth; human-practice boundedness is high—commerce, policy, employment, and organized production are social practices; and import versus recognition favors import—calling a generic causal network CDoH imports a particular public-health frame rather than recognizing a universal relation.

Its character: framed. The framework organizes real causal structure, yet without the health, equity, and commercial frame it becomes generic systems causation.

Structural Core vs. Domain Accent¶

Deletion test. Delete commercial actor, profit, product and practice, population health, and inequity. A multilevel causal graph remains, but it cannot distinguish CDoH from environmental, governmental, familial, or biological determinants. Identity fails.

Replacement test. Replace commercial firms with a volcanic process, lobbying with lava flow, and health inequity with spatial damage. Causality survives, but commerce and public-health governance do not; the result is another causal system.

Free-substitution test. Actor–practice–pathway reasoning transfers, but substrates cannot be substituted freely while preserving the field's outcome measures, ethical commitments, evidence rules, and intervention surfaces. The node fails the prime bar while remaining a coherent and reusable domain-specific abstraction.

CDoH instantiates Systems Thinking because it analyzes population health through relationships and feedback among commercial actors, products, practices, governance, environments, and populations rather than isolating one downstream choice. It presupposes Causality because the word “determinant” carries a cause-effect commitment that association alone cannot discharge.

Externality captures unpriced spillovers such as pollution and antimicrobial resistance but not every purchased-product, labor, access, or political pathway. Conflict of Interest diagnoses incompatible commercial and public-health incentives in partnerships, research, or governance. Regulatory Capture names the specific inversion in which regulated actors redirect regulators; Market Power helps explain price, labor, supply, and policy leverage. The Iron Triangle of Health Care concerns the access–quality–cost frontier inside health-system production and is therefore a neighboring health-policy abstraction, not coverage of commercial determinants across sectors.

Prospective DAG placement is documented separately in CATALOG_MATCH_AND_DAG_PLACEMENT.md; no structured edge is encoded in this isolated draft.

Relationships to Other Abstractions¶

Current abstraction Commercial Determinants of Health Domain-specific

Parents (2) — more general patterns this builds on

Commercial Determinants of Health is a kind of Systems Thinking Prime

CDoH instantiates Systems Thinking because it analyzes population health through relationships and feedback among commercial actors, products, practices, governance, environments, and populations rather than isolating one downstream.
Commercial Determinants of Health presupposes Causality Prime

CDoH instantiates Systems Thinking because it analyzes population health through relationships and feedback among commercial actors, products, practices, governance, environments, and populations rather than isolating one downstream.

Hierarchy paths (4) — routes to 4 parentless roots

Commercial Determinants of Health → Systems Thinking → Emergence → Micro Macro Linkage

Show alternative paths (3)

Neighborhood in Abstraction Space¶

Commercial Determinants of Health sits in a sparse region of the domain-specific corpus (80^th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.

Family — Unclustered & Miscellaneous (1565 abstractions)

Nearest neighbors

Computed from structural-signature embeddings · 2026-09-08

Not to Be Confused With¶

Social determinants of health: the broader conditions and systems shaping health. Tell: a social determinant need not involve paid or commercially organized activity pursuing a commercial or revenue-sustaining objective.
Economic determinants of health: income, wealth, macroeconomic policy, and material distribution more generally. Tell: an economic cause may be public or household-level rather than commercial practice.
Corporate determinants of health: a narrower actor formulation centered on corporations. Tell: CDoH also includes smaller, informal, hybrid, and other commercial entities.
Unhealthy commodity industries: an important application class. Tell: CDoH also covers services, work, finance, political activity, and beneficial products.
Externality: an unpriced third-party effect. Tell: direct product use, employment, knowledge, or access can be a CDoH pathway without meeting the externality definition.
Conflict of Interest: incompatible duties or incentives. Tell: a CDoH product or labor pathway can exist without a fiduciary or institutional conflict.
Regulatory Capture: regulated actors redirecting a regulatory institution. Tell: capture is one political pathway, not the whole commercial-health map.
Corporate social responsibility: voluntary social or environmental action and its communication. Tell: it is one possible beneficial practice or reputational pathway, not the determinant framework.
ESG assessment: a firm-rating or investment framework. Tell: CDoH asks for causal population-health and equity pathways rather than a composite score.
Health-care commercialization: market provision and finance within the health sector. Tell: CDoH ranges across all sectors whose commercial activity affects health.
Consumer behavior: purchasing or use by individuals. Tell: behavior is usually an intermediate node, not the upstream commercial determinant itself.
Anti-business advocacy: a political stance. Tell: valid CDoH analysis records beneficial, harmful, mixed, and uncertain effects with actor and pathway specificity.

References¶

[1] World Health Organization, “Commercial Determinants of Health”, fact sheet, 21 March 2023. registry ↩a ↩b ↩c ↩d ↩e

[2] Anna B. Gilmore et al., “Defining and Conceptualising the Commercial Determinants of Health”, The Lancet 401(10383), 1194–1213, 2023. registry ↩a ↩b ↩c

[3] Ilona Kickbusch, Luke Allen, and Christian Franz, “The Commercial Determinants of Health”, The Lancet Global Health 4(12), e895–e896, 2016. registry ↩

[4] Jennifer Lacy-Nichols et al., “Conceptualising Commercial Entities in Public Health: Beyond Unhealthy Commodities and Transnational Corporations”, The Lancet 401(10383), 1214–1228, 2023. registry ↩a ↩b ↩c

[5] Melissa Mialon, “An Overview of the Commercial Determinants of Health”, Globalization and Health 16, 74, 2020. registry ↩

[6] Sharon Friel et al., “Commercial Determinants of Health: Future Directions”, The Lancet 401(10383), 1229–1240, 2023. registry ↩